NCT04360941 - PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 11, 2020

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Triple Negative Breast CancerLocally Advanced Breast CancerRecurrent Breast CancerMetastatic Breast CancerER+ Breast CancerHER2-positive Breast Cancer

Interventions

DRUG

Palbociclib

Highly selective oral inhibitor of CDK4 and CDK6.

DRUG

Avelumab

Fully human IgG1 monoclonal antibody (mAb) binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.

Trial Locations (9)

M20 4BX

RECRUITING

The Christie NHS Foundation Trust, Manchester

CB2 0QQ

RECRUITING

Addenbrooke's Hospital Cambridge University Hospitals NHS Foundation Trust, Cambridge

G12 0YN

RECRUITING

Beatson West of Scotland Cancer Centre, Glasgow

LE1 5WW

RECRUITING

Hope Clinical Trials Cancer Centre, Leicester

EC1M 6BQ

RECRUITING

Barts Cancer Institute, London

SW3 6JJ

RECRUITING

Royal Marsden NHS Foundation Trust, London

W1T 7HA

RECRUITING

University College London Hospitals NHS Foundation Trust, London

NG5 1PB

RECRUITING

Nottingham University Hospital, Nottingham

S10 2SJ

RECRUITING

Weston Park Hospital, Sheffield